News | March 07, 2012

Biomarkers Proves Useful in Predicting Chronic Heart Failure Outcomes

Presage ST2 Assay

March 7, 2012 — Critical Diagnostics announced results from a multi-center study in ambulatory heart failure patients which confirmed that a contemporary panel of biomarkers, including ST2, was strongly predictive of risk and significantly improved the likelihood of identifying patients at risk for adverse events, compared to the most commonly used clinical risk score in heart failure, the Seattle Heart Failure Model (SHFM). The paper (“Multiple Biomarkers for Risk Prediction in Chronic Heart Failure”) was published online in Circulation: Heart Failure.

The Penn Heart Failure Study (PHFS), a multi-center cohort of 1,513 outpatients with chronic heart failure, used a panel of seven biomarkers, including ST2 as measured using the Presage ST2 Assay, and compared results to the most widely validated risk score, the Seattle Heart Failure Model (SHFM). During the follow-up period of 30 months, 187 patients died, 99 had cardiac transplants, and 31 had a ventricular assist device (VAD) placed. Patients in the highest one-third of the multi-marker score had a 13.7-fold increased risk of adverse outcomes compared to the lowest one-third, and this risk remained nearly seven-fold higher after adjustment for the SHFM. Moreover, the PHFS panel appropriately reclassified a significant number of patients — some 25 percent — into a higher risk category.

“This study provides continued support for the value of the Presage ST2 Assay in risk-stratifying patients with heart failure to better manage their condition,” states James Snider, president of Critical Diagnostics.

The Presage ST2 Assay quantitatively measures the level of ST2 in blood. ST2 has been shown to be a significant predictor of mortality as well as all-cause hospitalization, mortality due to cardiovascular disease, and hospitalization due to cardiovascular disease. ST2 is prognostic for clinically important outcomes in addition to all-cause mortality. Presage ST2 Assay levels are independent and complimentary of natriuretic peptide markers and not adversely affected by such confounding factors as age, gender, body mass index and impaired renal failure.

For more information: www.criticaldiagnostics.com

Related Content

First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing| September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Overlay Init